Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
GlobalData predicts the average prices of dual chamber pacemakers in both India and China are expected to reduce at an average CAGR of -3.42% from 2022 to 2025.
The use of procalcitonin testing for sepsis management is highest in the US
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
Aveir VR is specifically designed to be retrieved when therapy needs to evolve or the device needs to be replaced
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
Subscribe To Our Newsletter & Stay Updated
